Respiratory waves according to guyton n hall physiology book
Give whole necroptosis pathway n what it is according to cell signalling
| Feature | Apoptosis | Classical Necrosis | Necroptosis |
|---|---|---|---|
| Controlled/programmed | Yes | No (passive/accidental) | Yes |
| Caspase-dependent | Yes | No | No (caspase-independent) |
| Plasma membrane rupture | No (membrane blebs) | Yes | Yes |
| Inflammation triggered | Minimal | Yes | Yes |
| ATP loss | No | Yes | Yes |
| ROS generation | Minimal | Yes | Yes |
| Lysosomal enzyme release | No | Yes | Yes |
Critical condition: Necroptosis preferentially occurs when caspase-8 is inactive or inhibited. Normally, active caspase-8 cleaves RIPK1 and RIPK3, suppressing necroptosis in favour of apoptosis. When caspases are blocked (e.g., by viral caspase inhibitors or pharmacological agents), the necroptotic cascade is unleashed.
Note: RIPK1 is not always required - in some TLR3/4 and viral RNA-triggered necroptosis, RIPK3 can be activated independently of RIPK1.

| Context | Role |
|---|---|
| Bone growth plate formation | Physiological necroptosis drives terminal differentiation |
| Viral infection (e.g., CMV) | Backup killing when viruses inhibit caspases |
| Ischemia-reperfusion injury (brain, kidney, liver) | Pathological RIPK3/MLKL activation |
| Steatohepatitis | Contributes to hepatocyte death |
| Acute pancreatitis | Cell death mechanism |
| Neurodegenerative diseases (Parkinson's) | Chronic neuronal death |
| Cancer | Potential target when apoptosis resistance develops |
"Necroptosis resembles necrosis morphologically, but like apoptosis is a genetically controlled form of cell death. Necroptosis is triggered by ligation of TNFR1 and by proteins found in RNA and DNA viruses. Necroptosis is caspase independent and depends on the RIPK1-RIPK3 complex. RIPK1-RIPK3 signaling leads to the phosphorylation of MLKL, which then forms pores in the plasma membrane. Release of cellular contents evokes an inflammatory reaction as in necrosis."
Can you tell me about the program of complex one and complex two formed in, uh, in the microcosmos? And also, what is the difference between a hikotozoon and necro- necrozoan?
When you say 'Complex I and Complex II formed in the necrosome' - do you mean the protein complexes formed during necroptosis signalling (e.g. TNFR1-associated Complex I and Complex II that decide between survival, apoptosis, and necroptosis)? · For 'hikotozoon vs necrozoan' - these terms are not standard medical/biology terms I recognise. Could you clarify what you mean?
Give whole necroptosis pathway n what it is according to cell signallingCan you tell me about the program of complex one and complex two formed in, uh, in the microcosmos? And also, what is the difference between a ripotosome n and necro- necrosome
TNFR1 Complex I Complex II necrosome ripoptosome necroptosis pathway cell signalling
https://www.abcam.com/en-us/technical-resources/guides/cell-…
TNF + TNFR1
↓
COMPLEX I (membrane-bound, pro-survival)
↓ (RIPK1 deubiquitination → RIPK1 released)
COMPLEX IIa / RIPOPTOSOME (cytosolic, pro-apoptotic)
↓ (if caspase-8 is blocked)
COMPLEX IIb / NECROSOME (cytosolic, pro-necroptotic)
↓
CELL DEATH by NECROPTOSIS
| Protein | Role |
|---|---|
| TRADD | Adaptor protein; first recruited to TNFR1 death domain |
| RIPK1 | Kinase; key scaffold protein |
| TRAF2 / TRAF5 | Ubiquitin E3 ligases |
| cIAP1 / cIAP2 | Cellular inhibitor of apoptosis proteins; E3 ligases |
| LUBAC (HOIL + HOIP) | Linear ubiquitin chain assembly complex |
| TAK1 complex | MAP kinase kinase kinase |
| IKK complex (IKK1, IKK2, NEMO) | IκB kinase complex |
Key regulatory check: A20 and CYLD are deubiquitinases that remove ubiquitin chains from RIPK1, thereby attenuating Complex I signalling. CYLD-mediated deubiquitination of RIPK1 is the critical switch that allows RIPK1 to dissociate from the membrane and form Complex II.
| Protein | Role |
|---|---|
| RIPK1 | Scaffold/kinase |
| FADD | Adaptor with death effector domain (DED) |
| Caspase-8 (pro-caspase-8) | Initiator caspase |
| cFLIP | Regulatory protein (can promote or inhibit) |
The ripoptosome is essentially Complex IIa+b together - it is the cytosolic platform from which either apoptosis OR necroptosis can be executed.
| Protein | Role |
|---|---|
| RIPK1 | Kinase; recruits RIPK3 via RHIM domain |
| RIPK3 | Executioner kinase; phosphorylates MLKL |
| MLKL | Final effector; pore-forming protein |
| Feature | Ripoptosome | Necrosome |
|---|---|---|
| Also called | Complex II / Complex IIa | Complex IIb |
| Location | Cytosolic | Cytosolic |
| Key components | RIPK1 + FADD + Caspase-8 (± cFLIP) | RIPK1 + RIPK3 + MLKL |
| How it forms | RIPK1 deubiquitinated → leaves Complex I → recruits FADD + Casp-8 | Ripoptosome matures when Caspase-8 is blocked |
| Caspase-8 status | Caspase-8 present (active) | Caspase-8 absent or inactive |
| RIPK1 fate | Cleaved and inactivated by Casp-8 | Intact; phosphorylates RIPK3 via RHIM |
| Outcome | APOPTOSIS | NECROPTOSIS |
| Inhibitor | z-VAD (caspase inhibitor blocks apoptosis) | Necrostatin-1 (RIPK1 inhibitor) |
| Inflammation | Minimal (clean death) | Massive (DAMPs released) |
| Key interaction | Death domain / DED interaction | RHIM-RHIM interaction between RIPK1 and RIPK3 |
TNF
│
▼
TNFR1 (membrane)
│
▼
COMPLEX I: TRADD–RIPK1–TRAF2–cIAP1/2–LUBAC
│ (RIPK1 polyubiquitinated → NF-κB → SURVIVAL)
│
│ [CYLD/A20 deubiquitinate RIPK1 → RIPK1 leaves membrane]
▼
RIPOPTOSOME (cytosol): RIPK1–FADD–Caspase-8
│
├──[Caspase-8 ACTIVE]──► Caspase-8 cleaves RIPK1 & RIPK3
│ ↓
│ APOPTOSIS
│
└──[Caspase-8 INACTIVE]──► RIPK1 intact → recruits RIPK3 via RHIM
↓
NECROSOME: RIPK1–RIPK3 (mutual phosphorylation)
↓
RIPK3 phosphorylates MLKL (T357/S358)
↓
MLKL oligomerizes → translocates to membrane
↓
Plasma membrane DISRUPTION
↓
TISSUE DAMAGE + CELL DEATH + INFLAMMATION
Can you tell me about the everything about what is the autophagy and its sites and then the new station in the station along with it and all the, uh, factory according to sensitive knowledge about auto factory?
Your message had some unclear voice-to-text terms. Which of these best matches what you meant? · Which source should I focus on?
Tell me about autophagy according to cell signalling what it is , types n pre initiation,initiation elongation all the signalling steps
~33 autophagy-related genes (Atg genes) have been identified in mammalian cells that coordinate this process.


| Condition | mTOR Activity | Autophagy |
|---|---|---|
| Nutrients plentiful, growth factors present | HIGH | OFF (inhibited) |
| Nutrient starvation, hypoxia, high temp | LOW | ON (activated) |
| Rapamycin treatment | Inhibited | Activated |

Nutrient deprivation / Stress
↓
mTOR INHIBITED
AMPK ACTIVATED
↓
ULK1/2 kinase activated
Beclin-1 regulation: Beclin-1 is normally held in check by Bcl-2 (antiapoptotic protein). When Bcl-2 binds Beclin-1, autophagy is suppressed. Under stress, Bcl-2 releases Beclin-1, freeing it to form the PI3K complex → autophagy is activated. This is a key cross-talk point between autophagy and apoptosis.
ATG12 + ATG7 (E1-like) → ATG12~ATG7
ATG12~ATG7 + ATG10 (E2-like) → ATG12~ATG10
ATG12 covalently conjugated to ATG5
ATG12–ATG5 complex + ATG16L1 → ATG12–ATG5–ATG16L1 trimeric complex
LC3-I (cytosolic, full-length)
↓ ATG4 (cysteine protease cleaves C-terminus)
LC3-I (processed, cytosolic)
↓ ATG7 (E1-like activation)
LC3-I~ATG7
↓ ATG3 (E2-like)
LC3-I + PE (phosphatidylethanolamine) [catalyzed by ATG12-ATG5-ATG16L1 as E3]
↓
LC3-II (PE-lipidated LC3; membrane-bound)
The two systems work in concert: ATG12-ATG5 facilitates LC3 lipidation; both complexes together drive membrane elongation and curvature.
| Step | Molecules | Function |
|---|---|---|
| Pre-initiation | mTOR (inhibitor), AMPK (activator) | Sense nutrient/energy status |
| Initiation | ULK1/2 + ATG13 + FIP200 + ATG101 | Activate Atg cascade; translocate to ER |
| Nucleation | VPS34 + Beclin-1 + ATG14L + VPS15 | Generate PI3P; nucleate phagophore |
| Elongation (System 1) | ATG12–ATG5–ATG16L1 | Scaffold; E3 ligase activity; outer membrane |
| Elongation (System 2) | LC3-I → LC3-II (via ATG7, ATG3, PE) | Membrane curvature, closure, cargo selection |
| Cargo capture | p62/SQSTM1, NBR1 (cargo receptors) | Link ubiquitinated cargo to LC3-II |
| Maturation | Rab7, LAMP-1/2, SNAREs | Autophagosome → lysosome fusion |
| Degradation | Lysosomal hydrolases | Break down cargo |
| Recycling | Nutrient exporters | Export metabolites for reuse |
| Subtype | Cargo | Receptor |
|---|---|---|
| Mitophagy | Damaged mitochondria | PINK1/Parkin pathway; NIX |
| Xenophagy | Intracellular bacteria/viruses | NDP52, p62, optineurin |
| Lipophagy | Lipid droplets | - |
| Aggrephagy | Protein aggregates | p62/SQSTM1 |
| Ribophagy | Ribosomes | - |
| Pexophagy | Peroxisomes | - |
| Disease | Autophagy Defect |
|---|---|
| Alzheimer disease | Impaired autophagosome maturation; accelerated neurodegeneration with Atg knockouts |
| Huntington disease | Mutant huntingtin impairs autophagy |
| Crohn's disease / IBD | SNPs in ATG16L1 gene |
| Cancer | Dual role: tumor suppression early (removes damaged organelles); tumor promotion late (supplies nutrients to hypoxic tumors) |
| Tuberculosis | Macrophage Atg5 knockout → increased TB susceptibility |
| Ischemia-reperfusion | Autophagy is protective; impaired flux worsens injury |